Cargando…
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427552/ https://www.ncbi.nlm.nih.gov/pubmed/37347406 http://dx.doi.org/10.1007/s12325-023-02526-w |
| _version_ | 1785090269268410368 |
|---|---|
| author | Bieber, Thomas Feist, Eugen Irvine, Alan D. Harigai, Masayoshi Haladyj, Ewa Ball, Susan Deberdt, Walter Issa, Maher Grond, Susanne Taylor, Peter C. |
| author_facet | Bieber, Thomas Feist, Eugen Irvine, Alan D. Harigai, Masayoshi Haladyj, Ewa Ball, Susan Deberdt, Walter Issa, Maher Grond, Susanne Taylor, Peter C. |
| author_sort | Bieber, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10427552 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104275522023-08-17 Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 Bieber, Thomas Feist, Eugen Irvine, Alan D. Harigai, Masayoshi Haladyj, Ewa Ball, Susan Deberdt, Walter Issa, Maher Grond, Susanne Taylor, Peter C. Adv Ther Correction Springer Healthcare 2023-06-22 2023 /pmc/articles/PMC10427552/ /pubmed/37347406 http://dx.doi.org/10.1007/s12325-023-02526-w Text en © Springer Healthcare Ltd., part of Springer Nature 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Bieber, Thomas Feist, Eugen Irvine, Alan D. Harigai, Masayoshi Haladyj, Ewa Ball, Susan Deberdt, Walter Issa, Maher Grond, Susanne Taylor, Peter C. Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title | Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title_full | Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title_fullStr | Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title_full_unstemmed | Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title_short | Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 |
| title_sort | correction to: a review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and covid-19 |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427552/ https://www.ncbi.nlm.nih.gov/pubmed/37347406 http://dx.doi.org/10.1007/s12325-023-02526-w |
| work_keys_str_mv | AT bieberthomas correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT feisteugen correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT irvinealand correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT harigaimasayoshi correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT haladyjewa correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT ballsusan correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT deberdtwalter correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT issamaher correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT grondsusanne correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 AT taylorpeterc correctiontoareviewofsafetyoutcomesfromclinicaltrialsofbaricitinibinrheumatologydermatologyandcovid19 |